RMCM
CRSP icon

Reynders McVeigh Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Reynders McVeigh Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Sell
31,065
-92,373
-75% -$4.87M 0.08% 75
2026
Q1 		$5.87M Buy
123,438
+6,924
+6% +$365K 0.3% 55
2025
Q4 		$6.11M Buy
116,514
+3,514
+3% +$210K 0.29% 57
2025
Q3 		$7.32M Buy
113,000
+1,569
+1% +$90.1K 0.34% 52
2025
Q2 		$5.42M Buy
111,431
+9,658
+9% +$374K 0.27% 60
2025
Q1 		$3.46M Buy
101,773
+4,086
+4% +$173K 0.19% 63
2024
Q4 		$3.85M Sell
97,687
-21,899
-18% -$1.03M 0.2% 60
2024
Q3 		$5.62M Buy
119,586
+4,913
+4% +$249K 0.3% 52
2024
Q2 		$6.19M Buy
114,673
+17,694
+18% +$1.02M 0.35% 49
2024
Q1 		$6.61M Buy
96,979
+4,931
+5% +$353K 0.38% 50
2023
Q4 		$5.76M Buy
92,048
+15,870
+21% +$877K 0.36% 53
2023
Q3 		$3.46M Buy
76,178
+26,180
+52% +$1.35M 0.24% 57
2023
Q2 		$2.81M Buy
49,998
+31,094
+164% +$1.76M 0.18% 66
2023
Q1 		$855K Buy
+18,904
New +$918K 0.06% 96
2022
Q4 		– Sell
-3,085
Closed -$202K – 213
2022
Q3 		$202K Buy
+3,085
New +$224K 0.02% 204
2022
Q2 		– Sell
-4,680
Closed -$294K – 224
2022
Q1 		$294K Buy
4,680
+1,815
+63% +$114K 0.02% 193
2021
Q4 		$217K Buy
2,865
+165
+6% +$14.4K 0.01% 229
2021
Q3 		$302K Buy
2,700
+95
+4% +$11.9K 0.02% 190
2021
Q2 		$422K Buy
2,605
+145
+6% +$17.6K 0.03% 169
2021
Q1 		$300K Buy
2,460
+20
+0.8% +$3.02K 0.02% 195
2020
Q4 		$374K Sell
2,440
-50
-2% -$5.91K 0.03% 172
2020
Q3 		$208K Buy
+2,490
New +$221K 0.02% 213

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Reynders McVeigh Capital Management's CRSP Position: Q2 2026 in Review

Reynders McVeigh Capital Management reduced its CRISPR Therapeutics (CRSP) stake by 75% in Q2 2026, selling an estimated $4.87M and leaving 31,065 shares worth $1.69M. The position accounts for 0.08% of the portfolio, ranked #75.

Reynders McVeigh Capital Management first reported a position in CRSP in Q3 2020 and has held it in 22 quarters since. The position peaked at $7.32M in Q3 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Reynders McVeigh Capital Management held 31,065 shares of CRISPR Therapeutics worth $1.69M as of Q2 2026.
  • Reynders McVeigh Capital Management sold 92,373 CRISPR Therapeutics shares in Q2 2026, an estimated $4.87M.
  • CRISPR Therapeutics made up 0.08% of Reynders McVeigh Capital Management's portfolio in Q2 2026, its #75 holding.
  • Reynders McVeigh Capital Management first reported a position in CRISPR Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • Reynders McVeigh Capital Management's CRISPR Therapeutics position peaked at $7.32M in Q3 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Reynders McVeigh Capital Management's 13F filing for Q2 2026, filed 15 Sep 2026.